mebeverine mylan 100 mg, capsule molle
mylan sas - chlorhydrate de mébévérine - capsule - 100,00 mg - composition pour une capsule > chlorhydrate de mébévérine : 100,00 mg - anti-spasmodique musculotrope.
mebeverine teva 100 mg, capsule molle
teva sante - chlorhydrate de mébévérine - capsule - 100,00 mg - composition pour une capsule > chlorhydrate de mébévérine : 100,00 mg - antispasmodique musculotrope.
chlorhydrate de mebeverine mylan 200 mg, gélule
mylan sas - chlorhydrate de mébévérine - gélule - 200,00 mg - composition pour une gélule > chlorhydrate de mébévérine : 200,00 mg - antispasmodique musculotrope
mebeverine sandoz 200 mg, comprimé pelliculé sécable
sandoz - chlorhydrate de mébévérine - comprimé - 200,00 mg - composition pour un comprimé > chlorhydrate de mébévérine : 200,00 mg
sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
duspatalin 135 mg compr. enr.
viatris healthcare sa-nv - chlorhydrate de mébévérine 135 mg - comprimé enrobé - 135 mg - chlorhydrate de mébévérine 135 mg - mebeverine
duspatalin retard 200 mg gél. lib. prol.
viatris healthcare sa-nv - chlorhydrate de mébévérine 200 mg - gélule à libération prolongée - 200 mg - chlorhydrate de mébévérine 200 mg - mebeverine
colopriv 100 mg, capsule
laboratoires expanscience - mébévérine (chlorhydrate de) - capsule - 100 mg - composition pour une capsule > mébévérine (chlorhydrate de) : 100 mg - antispasmodique musculotrope.
sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
vildagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabète sucré, type 2 - les médicaments utilisés dans le diabète - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 et 5. 1 pour les données disponibles sur différentes combinaisons).